Co-Diagnostics Executes 1-for-30 Reverse Stock Split to Maintain Nasdaq Listing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 30 2025
0mins
Source: PRnewswire
- Reverse Stock Split: Co-Diagnostics announced a 1-for-30 reverse stock split effective January 2, 2026, aimed at regaining compliance with Nasdaq's minimum bid price requirement of $1.00, thereby mitigating delisting risks.
- Shareholder Approval: The reverse split was approved by shareholders at a special meeting on December 5, 2025, reflecting strong support for corporate governance and future growth, which enhances market confidence.
- Stock Trading Adjustment: Following the reverse split, Co-Diagnostics' stock will continue trading on Nasdaq under the new CUSIP number 189763 204, ensuring a smooth transition for investors into the adjusted trading environment.
- Equity Incentive Impact: The split will affect the number of stock options and warrants outstanding, with a corresponding increase in exercise prices, which is expected to enhance stock price stability and bolster investor confidence.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like CODX with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on CODX
Wall Street analysts forecast CODX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CODX is 1.50 USD with a low forecast of 1.50 USD and a high forecast of 1.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 2.360
Low
1.50
Averages
1.50
High
1.50
Current: 2.360
Low
1.50
Averages
1.50
High
1.50
About CODX
Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Co-Diagnostics Strengthens Distributor Network in India with CoSara
- Distributor Network Expansion: CoSara Diagnostics has strengthened its distributor base in India, exceeding 40 distributors, and enhanced market penetration through participation in regional conferences.
- Product Promotion Opportunities: At two recent regional conferences, CoSara introduced its SARAGENE® diagnostic products and the upcoming Co-Dx™ PCR platform, attracting new customers and solidifying existing relationships.
- Clinical Study Preparation: CoSara is preparing to assist in clinical performance studies for the Co-Dx PCR Mycobacterium Tuberculosis test, demonstrating its active involvement in public health initiatives.
- Manufacturing Collaboration: CoSara will participate in the production of the PCR Pro™ instrument and MTB test cups, supporting the
Continue Reading
Co-Diagnostics Strengthens Distributor Network in India with CoSara, Expanding to Over 40 Distributors
- Distributor Network Expansion: CoSara Diagnostics is strengthening its distribution network in India by participating in two regional conferences, successfully attracting new customers and expanding its base of over 40 distributors, indicating positive progress in market penetration.
- Product Promotion Opportunities: At the conferences, CoSara introduced its SARAGENE® diagnostic products and the upcoming Co-Dx™ PCR platform, aiming to enhance brand visibility and lay the groundwork for future sales, further driving growth in the Indian market.
- Clinical Study Preparation: CoSara is preparing for clinical performance studies for the Co-Dx PCR Mycobacterium Tuberculosis (MTB) test, which not only helps enhance product market recognition but also strengthens its influence in public health.
- Manufacturing Collaboration: CoSara will participate in the manufacturing of the PCR Pro™ instrument and MTB test cups, supporting the
Continue Reading